KEDPlasma acquires two plasma centers from ImmunoTek LLC in the US
The acquisition is part of a five-year growth plan of supplying highest-quality plasma to Kedrion Biopharma
Human rabies Ig meets primary endpoint in U.S. pivotal phase 2/3 clinical trial
Strategic agreement between Kedrion and Kamada for its clinical development and marketing
Hemophilia A. SIPPET study selected by the American Society of Hematology
Presented at the ASH Congress in Orlando, it was chosen from amongst approximately three thousand studies
Kedrion among the key players of Farmindustria’s roadshow in Siena
The Lucca-based company presented as one of the innovative pharmaceutical companies in Tuscany
Kedrion supports Fondazione Paracelso’s activities in Afghanistan
Kedrion confirms its commitment to broaden access to hemophilia treatments in developing Countries
Kedrion Notes 2019 Tender Offer results
Kedrion has accepted for purchase Notes validly tendered for a total aggregate principal amount equal to €150,716,000
Cash Tender Offer for Notes due 24 April 2019
Kedrion S.p.A. announced Cash Tender Offer for its €300,000,000 4.625 per cent. outstanding Notes due 24 April 2019
KEDPlasma welcomes donors to its new Augsburg collection center
Plasma collected in Germany is essential to Kedrion Biopharma’s plasma-derived therapies
Revolutionary PID testing from Tuscany, Italy
Kedrion at Meyer Hospital’s side to promote early diagnosis of primary immunodeficiencies
Humanitarian programme to reduce the gap in the access to clotting factors
Kedrion helps the WISH project come true: Italian CNS and the World Federation of Hemophilia sign agreement in London